Click here for slides on this topic


Lipid

A water-insoluble fatty substance. An abnormal amount of lipids in the blood is a condition called dyslipidemia.
The following content matched the glossary term: Lipid

ADA 2016 Children & Adolescents

Top

Recommendations for treating and managing diabetes in children from the 2016 ADA guidelines

ADA 2016 Cardiovascular Disease (CVD) and Diabetes

Top

Recommendations for CVD management, including lipids and BP, in patients with type 2 diabetes from the 2016 ADA diabetes guidelines

ADA 2016 Glycemic Targets

Top

Glycemic targets and A1C for adults with diabetes from the 2016 ADA guidelines

American Heart Association (AHA) Scientific Sessions 2012

Top

Exclusive coverage of late-breaking data from the American Heart Association Scientific Sessions, November 3-7, 2012 in Los Angeles, California are featured in this issue of OnsiteInsight®.

Health benefits of gastric bypass surgery after 6 years

Top

Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308(11):1122-1131. This prospective study by Adams and colleagues explored the weight loss and cardiometabolic benefits of Roux-en-Y gastric bypass (RYGB) among severely obese patients over 6 years of follow-up.

Awards - NDEI received top honors as the Best Internet Website at the Eighth Annual Healthcare Internet Conference

Top

NDEI.org received top honors as the Best Internet Website at the Eighth Annual Healthcare Internet Conference. The National Diabetes Education Initiative® (NDEI®) website, NDEI.org, received top honors as the Best Internet Website at the Eighth Annual Healthcare Internet Conference in Las Vegas, Nevada, on November 9, 2004.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin

Top

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. A recent position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) cites metformin as the optimal first-line drug for diabetes treatment. However, the statement acknowledges that limited data exist regarding treatments to be used beyond metformin.

Risk of cardiovascular and all-cause mortality: impact of impaired health-related functioning and diabetes: AusDiab study

Top

Williams ED, Rawal L, Oldenburg BF, Renwick C, Shaw JE, Tapp RJ. Risk of cardiovascular and all-cause mortality: impact of impaired health-related functioning and diabetes: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. Diabetes Care. 2012;35:1067-1073. In this substudy of the Australian Diabetes, Obesity and Lifestyle (AusDiab) study, Williams and colleagues demonstrated for the first time that combined exposure to type 2 diabetes and health-related functioning is associated with an increased risk of both cardiovascular (CV) and all-cause mortality.

Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity

Top

Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420-1428. The authors of the current prospective study sought to examine the potential benefits of laparoscopic Roux-en-Y gastric bypass (LRYGB) among those with BMI 30-34.9 kg/m2 (class I obesity) and type 2 diabetes.

Effects of intensive glucose lowering in type 2 diabetes

Top

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study investigated the effects of intensive glucose-lowering therapy on CV event reduction among patients with type 2 diabetes and either risk factors for, or established, cardiovascular disease.

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Lipid Slides Found: 170
Effect of Pioglitazone Monotherapy on Lipid Levels
Effect of Pioglitazone on Lipid Levels
Homozygous Mutation in Melanocortin-4 Receptor Gene
Increased Fructose Consumption and the Rise in Obesity
Low-Carbohydrate Diet vs Low-Fat Diet
Adiponectin and CRP Levels in Healthy Obese Women
Effect of Sibutramine on Weight Loss in Obese Patients With Type 2 Diabetes Treated With Sulfonylurea
Effect of Sibutramine on Weight Loss in Obese Patients With Type 2 Diabetes Treated With Metformin
Effect of Continuous and Intermittent Sibutramine on Lipids
Effect of Orlistat on Lipids and Glycemic Control in Patients
Effect of Pioglitazone Monotherapy on Lipid Levels
Effect of Pioglitazone on Lipid Levels
Improvement of Lipid Profiles: Morbidity and Mortality Improvement of Lipid Profiles in Patients With Diabetes Reduces Cardiovascular Morbidity and Mortality
ACP Guidelines on Management of Dyslipidemia in Type 2 Diabetes
Results From Statin Trials for Patients With Diabetes
GLAI: Enrollment Criteria
ALLHAT: Clinical Outcomes in Antihypertensive Treatments
Pioglitazone Reduces VLDL-TG Levels by Increasing LPL-Mediated Lipolysis
PROactive: Objective/Endpoints
Non–HDL-C as a Predictor of Risk for CHD in Diabetes
Glucagon-Like Peptide-1
Vildagliptin Is as Effective as Rosiglitazone in Lowering A1C but Without Weight Gain in Drug-Naïve Patients With T2D
TNT: Intensive Atorvastatin Treatment Reduces Cardiovascular Events in Patients With CHD and Diabetes
Diet Does Not Affect BP in Patients With Type 2 Diabetes in the Short-Term
High-Carbohydrate Diet Elevates BP in Patients With Type 2 Diabetes
ALLHAT: Reduced Diabetes Risk With Lisinopril
Compelling Indications for Hypertension Drug Classes (1 of 2)
GLAI: Comparison of TZDs on Lipoprotein Subclass Particle Size
Proportion of Diabetic Patients With Low HDL-C Stratified by Treatment, Sex, and Cardiovascular Disease
Steno-2: Percentage of Patients at Treatment Goals at End of Study
ACCORD: Study Design
ADVANCE: Study Design
Alogliptin and Glyburide Combination Therapy: A1C
ACCORD-MIND: Relationship Between Glycemia Status, Diabetes Duration, and Cognitive Test Scores
ACCORD-MIND: Relationship Between Glycemia Status, CVD, Stroke, Smoking Status, and Cognitive Test Scores
Efficacy of Pioglitazone Plus Sibutramine in Metformin-Intolerant vs Metformin-Tolerant Obese Subjects With Type 2 Diabetes
Impact of Higher Heart Rate on Development of Cardiometabolic Risk Factors After 20 Years
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
STAMPEDE: Design
ACP: Considerations for Oral Pharmacologic Therapy in Type 2 Diabetes
ORIGIN Omega-3 Fatty Acid Trial: Mean Change in Lipids
CONQUER: Design
SEQUEL: Design Extension of CONQUER Study
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile
JUPITER: Lipid and HsCRP Levels
AusDiab Substudy: Results
AusDiab Substudy: Physical Health Component Summary (PCS) Results
AusDiab Substudy: Mental Health Component Summary (MCS) Results
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Design
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Additional Parameters
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: CV Safety, Glucose, Adverse Events
RYGB Surgery: Long-Term Health-Related Outcomes Design
Comorbidities in Children and Adolescents With Type 2 Diabetes: Dyslipidemia (1 of 2)
Comorbidities in Children and Adolescents With Type 2 Diabetes: Dyslipidemia (2 of 2)
AIM-HIGH: Lipid Values at Baseline and 2 Years
CANTATA-D2: Design
CANTATA-D2: Effect of Canagliflozin Vs Sitagliptin on Lipid Values at 52 Weeks
CANTATA-M: Effect of Canagliflozin Vs Placebo on Lipid Values at 26 Weeks
CANTATA-M: Design
Meta-Analysis: Risk for New-Onset Diabetes and CV Events with Intensive- Vs Moderate Dose Statins
Meta-Analysis: New-Onset Diabetes and CV Events With Intensive- Vs Moderate-Dose Statins
Meta-Analysis: New-Onset Diabetes With Intensive- Vs Moderate-Dose Statins
Meta-Analysis: CV Events With Intensive- Vs Moderate-Dose Statins
LABS-2: 3-Yr Weight Loss After Bariatric Surgery
LABS-2: 3-Yr Mortality After Bariatric Surgery
LABS-2: 3-Yr Remission & Incidence of Cardiometabolic Outcomes After Bariatric Surgery
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 Years or Younger
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 and Older
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75 With Diabetes or LDL 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75, LDL 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Guidance on Nonstatin Therapies
AHA/ACC/TOS Obesity Guidelines: Weight Loss Outcomes in Overweight or Obese Adults
AHA/ACC/TOS Obesity Guidelines: Counseling on Benefits of Weight Loss
AleCardio: Design
STAMPEDE: A1C Less Than or Equal to 6.0 Percent at 3 Yrs With Bariatric Surgery Vs Medical Therapy
ACC/AHA Lifestyle Management Guidelines LDL-C | NDEI
ACC/AHA Lifestyle Management Mediterranean Diet Lipids BP | NDEI
ACC/AHA Lifestyle Guidelines DASH Diet Lipids BP | NDEI
DASH Diet ACC/AHA 2013 Lifestyle Management Guidelines | NDEI
DASH Diet Lipids BP ACC AHA Lifestyle Management Guidelines | NDEI
ACC AHA Lifestyle Guidelines Saturated Fat Lipid Lowering | NDEI
ACC AHA Lifestyle Guidelines Trans Fat Cholesterol | NDEI
Physical Activity Blood Pressure Lipids ACC AHA Lifestyle Guideline | NDEI
IDF Type 2 Diabetes Guidelines Cardiovascular Risk | NDEI
IDF Type 2 Diabetes Guidelines CVD Risk Reduction Treatment | NDEI
Canola Oil Glycemia A1C Type 2 Diabetes | NDEI
Canola Oil Glycemic Control CVD Type 2 Diabetes | NDEI
Canola Oil Study Glycemic Control A1C Type 2 Diabetes | NDEI
Canola Oil Diet Study Glycemia A1C Type 2 Diabetes | NDEI
JNC 8 Guidelines First-Line Antihypertensive Therapy for Black Patients | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Macrovascular Slides PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Linked to Inflammation Slides PPT | NDEI
Edinburgh Type 2 Diabetes Inflammation Doesn't Influence Hypoglycemia Slides PPT | NDEI
VA BEACH DIET Study: Impact of Diet on CVD Risk | NDEI
CVD Treatment Statin ADA Type 1 Diabetes Guidelines | NDEI
ADA EASD Hyperglycemia Management in Type 2 Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Cardiovascular Disease Targets | NDEI
AACE 2015 Guidelines Managing Dyslipidemia in Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Dyslipidemia Treatment PPT | NDEI
Cholesterol Targets LDL Type 2 Diabetes AHA ADA Guidelines | NDEI
ACCORD BP Post-hoc Analysis: Design
Lipid Management Recommendations ADA Diabetes Guidelines | NDEI
Statin Therapy in Type 2 Diabetes ADA Guidelines 2016 | NDEI PPT
Combination Statin Therapy in Type 2 Diabetes ADA Guidelines | NDEI PPT
Statin Therapy Recommendations for Type 2 Diabetes ADA Guidelines | NDEI
GAUSS-3 Design Evolocumab Vs Ezetimibe in Statin Intolerance | NDEI
HOPE-3 Primary Prevention for Individuals at Intermediate CV Risk
HOPE-3 Statin Therapy for Intermediate CV Risk Reduction PPT | NDEI
HOPE-3 CV Event Reduction With Rosuvastatin Vs Placebo PPT | NDEI
HOPE-3 LDL & Lipoprotein Reductions With Rosuvastatin Vs Placebo | NDEI
HOPE-3 Safety of Rosuvastatin Vs Placebo PPT | NDEI
HOPE-3 Incidence Diabetes With Rosuvatatin Vs Placebo PPT | NDEI
HOPE-3 CV Event Reduction With Antihypertensive Therapy PPT | NDEI
HOPE-3 BP Reductions With Candesartan/HCTZ Vs Placebo PPT | NDEI
HOPE-3 Safety of Candesartan/HCTZ Vs Placebo BP PPT | NDEI
HOPE-3 Cholesterol- and BP-Lowering for Intermediate CV Risk Reduction | NDEI
HOPE-3 Lipid- & BP-Lowering Therapy for Primary Prevention PPT | NDEI
HOPE-3 Lipid- & BP-Lowering Intermediate Risk CV Events PPT | NDEI
Lifestyle Recommendations from the NLA Cholesterol Guidelines | CCMD
Diets for Cholesterol Lowering NLA Cholesterol Guidelines | CCMD
Nutrition Recommendations NLA Cholesterol Guidelines | CCMD
Nutrition Recommendations to Treat High TG NLA Cholesterol Guidelines | CCMD
Lipid Screening in Children & Adolescents NLA Cholesterol Guidelines | CCMD
Lipoprotein Screening in Children & Adolescents NLA Cholesterol Guidelines | CCMD
Cascade Screening ifor FH in Children & Adolescents NLA Cholesterol Guidelines
Lifestyle Interventions for Children & Adolescents NLA Cholesterol Guidelines
Lipid Pharmacotherapy for Children & Adolescents NLA Cholesterol Guidelines
Treating Dyslipidemia in Women NLA Cholesterol Guidelines | CCMD
Pharmacologic Therapy for Dyslipidemia in Women NLA Cholesterol Guidelines
Managing Dyslipidemia During Pregnancy NLA Cholesterol Guidelines | CCMD
Managing Dyslipidemia in Women With PCOS NLA Cholesterol Guidelines
Managing Dyslipidemia in Women During Menopause NLA Cholesterol Guidelines
Primary & Secondary ASCVD Prevention in Older Adults NLA Cholesterol Guidelines
ASCVD Risk Assessment in Older Adults NLA Cholesterol Guidelines | CCMD
Pharmacotherapy for Dyslipidemia in Older Adults NLA Cholesterol Guidelines
Managing Dyslipidemia in Hispanics/Latinos NLA Cholesterol Guidelines | CCMD
Managing Dyslipidemia in African-Americans NLA Cholesterol Guidelines
Managing Dyslipidemia in Individuals With HIV NLA Cholesterol Guidelines
Managing Residual Risk After Lifestyle & Statin Therapy NLA Cholesterol Guidelines
PCSK9 Inhibitors for Residual CV Risk NLA Cholesterol Guidelines | CCMD
NLA Dyslipidemia Guidelines Summary CVD Slides | CCMD
NLA Cholesterol Guidelines LDL-C Treatment Targets | CCMD
NLA Cholesterol Guidelines Lipid Screening Recommendations PPT | CCMD
NLA Cholesterol Guidelines Lipid Treatment Goals | CCMD
NLA Guidelines Cholesterol & Triglyceride Targets CVD Slides | CCMD
NLA Guidelines Cholesterol Targets for Therapy CVD Slides | CCMD
NLA Guidelines Atherogenic Cholesterol Levels for Primary Prevention | CCMD
NLA Cholesterol Guidelines Lipid Treatment Goals | CCMD
NLA Guidelines CVD Risk Categories & Lipid Treatment | CCMD
NLA Cholesterol Guidelines Metabolic Syndrome Criteria | CCMD
NLA Cholesterol Guidelines ASCVD Risk Factors Slides | CCMD PPT
NLA Cholesterol Guidelines High or Very-High ASCVD Risk | CCMD
Very-High ASCVD Risk LDL Goals NLA Cholesterol Guidelines | CCMD
LDL-C Target for High ASCVD Risk NLA Cholesterol Guidelines | CCMD
NLA Cholesterol Guidelines Moderate ASCVD Risk PPT | CCMD
NLA Cholesterol Guidelines Low ASCVD Risk PPT | CCMD
ASCVD Risk Assessment Algorithm NLA Cholesterol Guidelines | CCMD
NLA Cholesterol Guidelines ASCVD Risk Refinement PPT | CCMD
NLA Cholesterol Guidelines Lifestyle Therapy ASCVD Risk PPT | CCMD
NLA Guidelines Patient-Centered Drug Therapy ASCVD Risk Reduction | CCMD
Cholesterol Treatment Algorithm to Reduce ASCVD NLA Guidelines | CCMD
Hypertriglyceridemia Management NLA Cholesterol Guidelines PPT | CCMD
Combination Lipid-Lowering Therapy NLA Cholesterol Guidelines PPT | CCMD
Severe Hypercholesterolemia Management FH NLA Cholesterol Guidelines | CCMD
FH Treatment & Management PCSK9 NLA Cholesterol Guidelines | CCMD
FH Treatment LDL-Apheresis NLA Cholesterol Guidelines PPT | CCMD
HOPE-3 BP-Lowering Arm: Statin Therapy for Intermediate CV Risk Reduction
Preoperative Workup Metabolic Surgery for Type 2 Diabetes Treatment | NDEI